134 related articles for article (PubMed ID: 11564018)
21. Outcomes of intrarenal Bacillus Calmette-Guérin/interferon-α2B for biopsy-proven upper-tract carcinoma in situ.
Shapiro EY; Lipsky MJ; Cha DY; McKiernan JM; Benson MC; Gupta M
J Endourol; 2012 Dec; 26(12):1645-50. PubMed ID: 22834939
[TBL] [Abstract][Full Text] [Related]
22. Should follow-up cystoscopy in bacillus Calmette-Guérin-treated patients continue after five tumour-free years?
Holmäng S; Ströck V
Eur Urol; 2012 Mar; 61(3):503-7. PubMed ID: 22119022
[TBL] [Abstract][Full Text] [Related]
23. Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up.
Järvinen R; Kaasinen E; Rintala E; Group TF
Scand J Urol Nephrol; 2012 Dec; 46(6):411-7. PubMed ID: 22746387
[TBL] [Abstract][Full Text] [Related]
24. Bacillus Calmette-Guérin perfusion therapy for carcinoma in situ of the upper urinary tract.
Yokogi H; Wada Y; Mizutani M; Igawa M; Ishibe T
Br J Urol; 1996 May; 77(5):676-9. PubMed ID: 8689109
[TBL] [Abstract][Full Text] [Related]
25. [Carcinoma in situ of the urinary tract--in patients with positive cytologies of upper urinary tract samples].
Kitamura Y; Kobayasi K; Suzuki K; Saito T; Komatsubara S; Watanabe M
Nihon Hinyokika Gakkai Zasshi; 2002 Jul; 93(5):621-6. PubMed ID: 12174638
[TBL] [Abstract][Full Text] [Related]
26. Intravesical instillation of bacille Calmette-Guérin for carcinoma in situ of the urothelium involving the upper urinary tract using vesicoureteral reflux created by a double-pigtail catheter.
Irie A; Iwamura M; Kadowaki K; Ohkawa A; Uchida T; Baba S
Urology; 2002 Jan; 59(1):53-7. PubMed ID: 11796281
[TBL] [Abstract][Full Text] [Related]
27. Risk of subsequent tumour recurrence and stage progression in bacille Calmette-Guérin relapsing non-muscle-invasive bladder cancer.
Matsumoto K; Kikuchi E; Shirakawa H; Hayakawa N; Tanaka N; Ninomiya A; Miyajima A; Nakamura S; Oya M
BJU Int; 2012 Dec; 110(11 Pt B):E508-13. PubMed ID: 22574662
[TBL] [Abstract][Full Text] [Related]
28. Topical instillation of BCG immunotherapy for biopsy-proven primary upper urinary tract carcinoma in situ: A single institution series and systematic review.
Fontanet S; Gallioli A; Baboudjian M; Huguet J; Territo A; Gaya JM; Gavrilov P; Izquierdo P; Verri P; Algaba F; Palou J; Breda A
Urol Oncol; 2023 Jun; 41(6):274-283. PubMed ID: 36526527
[TBL] [Abstract][Full Text] [Related]
29. Impact of bacillus Calmette-Guérin therapy of upper urinary tract carcinoma in situ: comparison of oncological outcomes with radical nephroureterectomy.
Horiguchi H; Yoneyama T; Hatakeyama S; Tokui N; Sato T; Fujita N; Yamamoto H; Tobisawa Y; Yoneyama T; Hashimoto Y; Koie T; Yoshikawa K; Narita S; Kawaguchi T; Ohyama C
Med Oncol; 2018 Feb; 35(4):41. PubMed ID: 29480348
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder.
Takenaka A; Yamada Y; Miyake H; Hara I; Fujisawa M
Int J Urol; 2008 Apr; 15(4):309-13. PubMed ID: 18380817
[TBL] [Abstract][Full Text] [Related]
31. Intravesical Bacillus Calmette-Guérin with the Danish strain for treatment of carcinoma in situ of the bladder.
Ovesen H; Poulsen AL; Steven K
Br J Urol; 1993 Nov; 72(5 Pt 2):744-8. PubMed ID: 8281407
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Tolerability of Bacillus Calmette-Guérin Therapy as the First-Line Therapy for Upper Urinary Tract Carcinoma In Situ.
Tomisaki I; Kubo T; Minato A; Fujimoto N
Cancer Invest; 2018 Feb; 36(2):152-157. PubMed ID: 29393701
[TBL] [Abstract][Full Text] [Related]
33. Long-term risk of progression of carcinoma in situ of the bladder and impact of bacille Calmette-Guérin immunotherapy on the outcome.
Zieger K; Jensen KM
Scand J Urol Nephrol; 2011 Dec; 45(6):411-8. PubMed ID: 21793636
[TBL] [Abstract][Full Text] [Related]
34. Effect of keyhole limpet hemocyanin (KLH) and bacillus Calmette-Guérin (BCG) instillation on carcinoma in situ of the urinary bladder.
Jurincic-Winkler C; Metz KA; Beuth J; Sippel J; Klippel KF
Anticancer Res; 1995; 15(6B):2771-6. PubMed ID: 8669862
[TBL] [Abstract][Full Text] [Related]
35. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
[TBL] [Abstract][Full Text] [Related]
36. Management of primary upper urinary tract carcinoma in situ diagnosed by ureteroscopic biopsy: Is bacillus Calmette-Guerin an alternative to nephroureterectomy?
Territo A; Fontanet S; Meneghetti I; Gallioli A; Sanguedolce F; Rodriguez-Faba Ó; Gaya JM; Palou J; Huguet J; Breda A
Actas Urol Esp (Engl Ed); 2023 May; 47(4):221-228. PubMed ID: 36379260
[TBL] [Abstract][Full Text] [Related]
37. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
38. Long term follow-up of intravesical Bacillus Calmette-Guerin for the treatment of bladder transitional cell carcinoma.
Leblanc B; Duclos AJ; Bénard F; Valiquette L; Paquin JM; Lapointe S; Mauffette F; Pharand D; Faucher R; Drouin G; Perreault JP
Can J Urol; 2000 Feb; 7(1):944-8. PubMed ID: 11121250
[TBL] [Abstract][Full Text] [Related]
39. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
Järvinen R; Kaasinen E; Sankila A; Rintala E;
Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
[TBL] [Abstract][Full Text] [Related]
40. [The influence over the long-term prognosis of BCG therapy and the surgical treatment in superficial bladder cancer treatment].
Higashi S; Matsui Y; Takahashi T; Nishiyama H; Ito N; Yamamoto S; Kamoto T; Ogawa O
Hinyokika Kiyo; 2005 Aug; 51(8):529-31. PubMed ID: 16164268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]